Spotlight on Emergency Medicine

Credits: 1.00 CME / CNE / CPE
Advances in the Management of Acute and Chronic Hyperkalemia
Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC
AcademicCME

Advances in the Management of Acute and Chronic Hyperkalemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 20, 2020
Expires: October 19, 2021
60 minutes to complete

Accredited By

Target Audience

Community and community hospital-based generalist and specialist physicians, nurses, and pharmacists who manage patients with hyperkalemia.

Learning Objectives

  • Assess for hyperkalemia risk in patients with underlying diseases like heart failure, diabetes, or chronic kidney disease
  • Understand and differentiate among therapies for temporizing, acute, and chronic therapy for hyperkalemia
  • Analyze the latest evidence-based data for hyperkalemia therapeutics to inform clinical decision making in an era of advanced treatment of heart failure, diabetes, and chronic kidney disease

Activity Description

Hyperkalemia and its important cardiometabolic comorbidities are increasingly common, while the most frequently used acute therapy to lower potassium levels for over five decades is now recognized as being associated with serious adverse effects. Over the last four years, clinical trial data has identified newer and safer therapeutic options. The goals of better potassium management include facilitation of guidelines-recommended therapy for heart failure and hypertension, and support of the patient with chronic renal disease. In this unique program, we will discuss new and improved options for managing hyperkalemia acutely and chronically. This information will impact the practices of emergency medicine physicians, hospitalists, internists, cardiologists, nephrologists, and other clinicians.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with hyperkalemia.

Agenda

  • Understand the Hyperkalemia Risk in Patients With Heart failure, Diabetes, or Chronic Kidney Disease
  • Acute and Temporizing Management of Hyperkalemia
  • Data Analysis and Interpretation: Applicability to Practice of Newer Potassium Binders

Faculty

Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Javed Butler, MD, MPH, MBA
Chairman and Professor
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack, Jr., MA, MD, FACEP, FAHA, FACC, FESC (Course Chair)
Relationship Identified With:
Grant/Research Support: AstraZeneca Pharmaceuticals; Boehringer-Ingelheim Pharmaceuticals; CSL Behring.

Javed Butler, MD, MPH, MBA
Relationship Identified With:
Consultant/Advisor: Amgen Inc.; Array; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVRX Inc.; G3 Pharmaceuticals; Innolife; Janssen Scientific Affairs LLC.; Luitpold Pharmaceuticals, Inc.; Merck & Co.; Medtronics; Novartis Pharmaceuticals Corporation; Relypsa Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-007-L04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  • Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 20, 2020
Expires: October 19, 2021
60 minutes to complete

Accredited By

Target Audience

Community and community hospital-based generalist and specialist physicians, nurses, and pharmacists who manage patients with hyperkalemia.

Learning Objectives

  • Assess for hyperkalemia risk in patients with underlying diseases like heart failure, diabetes, or chronic kidney disease
  • Understand and differentiate among therapies for temporizing, acute, and chronic therapy for hyperkalemia
  • Analyze the latest evidence-based data for hyperkalemia therapeutics to inform clinical decision making in an era of advanced treatment of heart failure, diabetes, and chronic kidney disease

Activity Description

Hyperkalemia and its important cardiometabolic comorbidities are increasingly common, while the most frequently used acute therapy to lower potassium levels for over five decades is now recognized as being associated with serious adverse effects. Over the last four years, clinical trial data has identified newer and safer therapeutic options. The goals of better potassium management include facilitation of guidelines-recommended therapy for heart failure and hypertension, and support of the patient with chronic renal disease. In this unique program, we will discuss new and improved options for managing hyperkalemia acutely and chronically. This information will impact the practices of emergency medicine physicians, hospitalists, internists, cardiologists, nephrologists, and other clinicians.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with hyperkalemia.

Agenda

  • Understand the Hyperkalemia Risk in Patients With Heart failure, Diabetes, or Chronic Kidney Disease
  • Acute and Temporizing Management of Hyperkalemia
  • Data Analysis and Interpretation: Applicability to Practice of Newer Potassium Binders

Faculty

Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Javed Butler, MD, MPH, MBA
Chairman and Professor
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack, Jr., MA, MD, FACEP, FAHA, FACC, FESC (Course Chair)
Relationship Identified With:
Grant/Research Support: AstraZeneca Pharmaceuticals; Boehringer-Ingelheim Pharmaceuticals; CSL Behring.

Javed Butler, MD, MPH, MBA
Relationship Identified With:
Consultant/Advisor: Amgen Inc.; Array; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVRX Inc.; G3 Pharmaceuticals; Innolife; Janssen Scientific Affairs LLC.; Luitpold Pharmaceuticals, Inc.; Merck & Co.; Medtronics; Novartis Pharmaceuticals Corporation; Relypsa Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-007-L04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  • Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Emergency Medicine Presentations

1.00 CME / CNE / CPE
AcademicCME
Advances in the Management of Acute and Chronic Hyperkalemia

Advances in the Management of Acute and Chronic Hyperkalemia

Start

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 20, 2020
Expires: October 19, 2021
60 minutes to complete

Accredited By

Target Audience

Community and community hospital-based generalist and specialist physicians, nurses, and pharmacists who manage patients with hyperkalemia.

Learning Objectives

  • Assess for hyperkalemia risk in patients with underlying diseases like heart failure, diabetes, or chronic kidney disease
  • Understand and differentiate among therapies for temporizing, acute, and chronic therapy for hyperkalemia
  • Analyze the latest evidence-based data for hyperkalemia therapeutics to inform clinical decision making in an era of advanced treatment of heart failure, diabetes, and chronic kidney disease

Activity Description

Hyperkalemia and its important cardiometabolic comorbidities are increasingly common, while the most frequently used acute therapy to lower potassium levels for over five decades is now recognized as being associated with serious adverse effects. Over the last four years, clinical trial data has identified newer and safer therapeutic options. The goals of better potassium management include facilitation of guidelines-recommended therapy for heart failure and hypertension, and support of the patient with chronic renal disease. In this unique program, we will discuss new and improved options for managing hyperkalemia acutely and chronically. This information will impact the practices of emergency medicine physicians, hospitalists, internists, cardiologists, nephrologists, and other clinicians.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with hyperkalemia.

Agenda

  • Understand the Hyperkalemia Risk in Patients With Heart failure, Diabetes, or Chronic Kidney Disease
  • Acute and Temporizing Management of Hyperkalemia
  • Data Analysis and Interpretation: Applicability to Practice of Newer Potassium Binders

Faculty

Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Javed Butler, MD, MPH, MBA
Chairman and Professor
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack, Jr., MA, MD, FACEP, FAHA, FACC, FESC (Course Chair)
Relationship Identified With:
Grant/Research Support: AstraZeneca Pharmaceuticals; Boehringer-Ingelheim Pharmaceuticals; CSL Behring.

Javed Butler, MD, MPH, MBA
Relationship Identified With:
Consultant/Advisor: Amgen Inc.; Array; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVRX Inc.; G3 Pharmaceuticals; Innolife; Janssen Scientific Affairs LLC.; Luitpold Pharmaceuticals, Inc.; Merck & Co.; Medtronics; Novartis Pharmaceuticals Corporation; Relypsa Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-007-L04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  • Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Free CME/CNE/CPE
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: October 20, 2020
Expires: October 19, 2021
60 minutes to complete

Accredited By

Target Audience

Community and community hospital-based generalist and specialist physicians, nurses, and pharmacists who manage patients with hyperkalemia.

Learning Objectives

  • Assess for hyperkalemia risk in patients with underlying diseases like heart failure, diabetes, or chronic kidney disease
  • Understand and differentiate among therapies for temporizing, acute, and chronic therapy for hyperkalemia
  • Analyze the latest evidence-based data for hyperkalemia therapeutics to inform clinical decision making in an era of advanced treatment of heart failure, diabetes, and chronic kidney disease

Activity Description

Hyperkalemia and its important cardiometabolic comorbidities are increasingly common, while the most frequently used acute therapy to lower potassium levels for over five decades is now recognized as being associated with serious adverse effects. Over the last four years, clinical trial data has identified newer and safer therapeutic options. The goals of better potassium management include facilitation of guidelines-recommended therapy for heart failure and hypertension, and support of the patient with chronic renal disease. In this unique program, we will discuss new and improved options for managing hyperkalemia acutely and chronically. This information will impact the practices of emergency medicine physicians, hospitalists, internists, cardiologists, nephrologists, and other clinicians.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with hyperkalemia.

Agenda

  • Understand the Hyperkalemia Risk in Patients With Heart failure, Diabetes, or Chronic Kidney Disease
  • Acute and Temporizing Management of Hyperkalemia
  • Data Analysis and Interpretation: Applicability to Practice of Newer Potassium Binders

Faculty

Charles V. Pollack Jr., MA, MD, FACEP, FAHA, FACC, FESC
Clinician-Scientist
Department of Emergency Medicine
University of Mississippi School of Medicine
Jackson, Mississippi


Javed Butler, MD, MPH, MBA
Chairman and Professor
Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Charles V. Pollack, Jr., MA, MD, FACEP, FAHA, FACC, FESC (Course Chair)
Relationship Identified With:
Grant/Research Support: AstraZeneca Pharmaceuticals; Boehringer-Ingelheim Pharmaceuticals; CSL Behring.

Javed Butler, MD, MPH, MBA
Relationship Identified With:
Consultant/Advisor: Amgen Inc.; Array; AstraZeneca Pharmaceuticals; Bayer AG; Boehringer Ingelheim; Bristol-Myers Squibb Company; CVRX Inc.; G3 Pharmaceuticals; Innolife; Janssen Scientific Affairs LLC.; Luitpold Pharmaceuticals, Inc.; Merck & Co.; Medtronics; Novartis Pharmaceuticals Corporation; Relypsa Inc.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour (Provider Number P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEU) of continuing pharmacy education credit (UAN #: JA4008190-0000-20-007-L04-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

  • Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  • Complete the Pre-Activity Questions.
  • Read or review the activity content.
  • Complete the Post-Activity Test Questions and Evaluation.
  • Learners who receive a grade of 66% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
    CPE credit will be posted to the learner's CPE Monitor profile within 60 days of completion.
    CME and CNE credit will be issued appropriate certificate of completion.
    Others may request a "certificate of completion".
  • Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from AstraZeneca Pharmaceuticals.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.